Small molecules which reverse Motexafin gadolinium treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00013371
TitleSmall molecules which reverse Motexafin gadolinium treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Motexafin gadolinium treatment in the Ramos B-cell lymphoma line cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1e44fe467bea600fb9592
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis Curatorcadimo
CREEDS IDdrug:3591
Cell TypeRamos B-cell lymphoma line
Drug NameMotexafin gadolinium
DrugBank IDDB05428
Organismhuman
SMILES ID[O-]C(=O)C.[O-]C(=O)C.OCCCC1=C(C)/C/2=C/N=c/3\cc(OCCOCCOCCOC)c(c\c3=N/C=C/3\N=C(/C=c/4\[n-]/c(=C\C1=N2)/c(CC)c4CC)C(=C3C)CCCO)OCCOCCOCCOC.[Gd+3]
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM64867, GSM64868, GSM64869
Perturbed SamplesGSM64876, GSM64877, GSM64878
Tools used in the analysis
Dataset Accession
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
Datasets used in the analysis
Keyword
Tool Name
GSE2964
Gene Expression Omnibus
Motexafin gadolinium and zinc effect on Ramos B-cell lymphoma line
21
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.